On July 27, 2020, MBX Biosciences, a drug discovery company focused in rare endocrine diseases, announced the closing of a $34.6 million Series A financing. The financing was led by Frazier Healthcare Partners, with participation from OrbiMed, New Enterprise Associates, Indiana Philanthropic Venture Fund (IU PhV), Indiana Seed Fund III (managed by BioCrossroads), and Twilight Venture Partners II. Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets. The company is built upon the medicinal expertise and chemical technologies invented at the Indiana University laboratory of Professor Richard DiMarchi, Ph.D., co-founder and chief scientific officer of MBX. The company seeks to address rare endocrine disorders with substantial unmet medical need.

The Wilson Sonsini Goodrich & Rosati that advised MBX Biosciences in patent matters related to the transaction includes Kenneth Clark, Marina Tsatalis, Michael Hostetler, Sean Reed, and Uale Taotafa.

For more information, please see MBX Biosciences' press release.